As decentralised clinical trials (DCTs) become ubiquitous, so do the ethical complexities involved in their design and oversight. How do you raise the ethical bar without compromising innovation?
In this International Clinical Trials* article, Univo IRB’s Bob Romanchuk outlines the critical ethical questions DCT designers must address — from informed consent and digital access, to privacy, participant safety, and equitable oversight. Read it to explore:
- What ethical issues are unique to decentralised clinical trials
- Recommendations for reviewing DCTs
- A checklist of best practices for participant rights, safety, and oversight
*International Clinical Trials, May 2025, pages 64-66. © Samedan Ltd.
